FDA Approves First Generic Versions of Farxiga (Dapagliflozin)
In a significant move for patient access and healthcare affordability, the U.S. Food and Drug Administration (FDA) approved the first generic versions of Farxiga (dapagliflozin) on April 7, 2026. This approval opens the door for multiple manufacturers to provide this critical medication, which is used to manage type 2 diabetes and reduce heart failure risks.
Farxiga, originally developed by AstraZeneca, has long been a cornerstone therapy for millions. The introduction of generics typically leads to increased competition and lower costs, making life-saving treatment more accessible to the 40 million Americans living with diabetes, 90% to 95% of whom have type 2 diabetes, according to the Centers for Disease Control and Prevention.
What is Dapagliflozin and How Does It Work?
Dapagliflozin belongs to a class of medications known as sodium-glucose cotransporter 2 (SGLT2) inhibitors. Unlike some diabetes medications that focus on insulin production or sensitivity, SGLT2 inhibitors target the kidneys.
The drug works by reducing the reabsorption of glucose and sodium in the kidneys, allowing the body to eliminate excess sugar through urine. This process helps lower blood glucose levels and provides additional cardiovascular benefits, particularly for those at risk of heart failure.
Approved Uses for Generic Dapagliflozin
The FDA-approved generic dapagliflozin tablets are available in 5mg and 10mg strengths. They are specifically indicated for:
- Glycemic Control: As an adjunct to diet and exercise to improve blood sugar levels in adults with type 2 diabetes mellitus.
- Heart Failure Risk Reduction: To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes who also have established cardiovascular disease or multiple cardiovascular risk factors.
Important Distinctions: Generic vs. Brand-Name Farxiga
Although the generic version provides a more affordable alternative for many, the current generic labeling is more limited than that of the brand-name Farxiga or its authorized generic. Patients and providers should be aware that the following indications are not currently included in the generic labeling:
- Chronic Kidney Disease (CKD): The generic is not labeled for reducing the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, or heart failure hospitalization in CKD patients.
- Broad Heart Failure Use: While the brand-name drug is approved to reduce cardiovascular death and heart failure hospitalizations in adults with heart failure regardless of left ventricular ejection fraction status, the generic is currently limited to those with type 2 diabetes.
- Pediatric Use: The generic approval excludes use in type 2 diabetes patients aged 10 years and older.
Safety, Warnings, and Side Effects
Generic dapagliflozin carries the same contraindications and warnings as the branded version. It is strictly contraindicated in patients with a history of serious hypersensitivity reactions to dapagliflozin or any of its excipients.
Key Safety Warnings:
- Ketoacidosis: There is a risk of diabetic ketoacidosis, particularly in patients with type 1 diabetes, as well as other forms of ketoacidosis.
- Volume Depletion: Patients should be monitored for signs of dehydration or low blood volume.
The most common side effects reported in clinical trials include urinary tract infections, nasopharyngitis, and female genital mycotic infections.
- The FDA approved the first generics of dapagliflozin on April 7, 2026.
- Generics are indicated for adults with type 2 diabetes and heart failure risk reduction in T2D patients.
- Current generic labels exclude pediatric use, chronic kidney disease indications, and heart failure treatment for non-diabetic patients.
- The drug is an SGLT2 inhibitor that helps the kidneys remove glucose from the body.
Frequently Asked Questions
Will my doctor switch me to the generic version automatically?
Switching depends on your specific medical needs. Because the generic version currently excludes certain indications—such as those for chronic kidney disease or pediatric use—your healthcare provider will determine if the generic is appropriate for your specific diagnosis.
Where can I find a full list of approved generic manufacturers?
The FDA recommends checking the Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”) for a complete list of approved manufacturers and contacting them directly for availability.
Conclusion
The approval of generic dapagliflozin is a positive step toward reducing the financial burden on patients managing type 2 diabetes and heart failure. While the generic version currently covers the primary uses for adult T2D patients, those requiring the broader indications held by Farxiga should continue to consult their physicians to ensure they receive the most appropriate therapy for their condition.